Besides, there were no significant difference in gender, diagnoses, CD34+ cells/kg BW, HLA-identical vs. mismatched, acute GvHD grade 0-II vs. III-IV, no/mild vs. moderate/severe chronic GvHD, relapse and OS when comparing the ATG- and the non-ATG-cohort (Table 1). This evidence concerns the gene CD34 and chronic graft versus host disease.